Verity Patent-Cliff Exposure & CMS Drug Spending Portfolio

Verity (US): 2 reconciled FDA prescription therapies (95.0% 2025 to 2030 cliff risk), $17.6M 2024 CMS Part D & Medicaid spend, and 5 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Headquarters / ClusterUS
Reconciled FDA Portfolio Therapies2
2025 to 2030 Patent-Cliff Revenue Exposure95.0%
Primary Portfolio LOE Date2029-01-01
2024 CMS Total Public Spend$17.6M
2024 Medicare Part D Spend$16.0M
2024 Medicaid Spend$1.6M
California HCAI SB 17 Filings5 WAC filings (max 29.2% 2-yr change)